BTIG Maintains Buy on Adicet Bio, Lowers Price Target to $10
Portfolio Pulse from Benzinga Newsdesk
BTIG analyst Justin Zelin maintains a Buy rating on Adicet Bio (NASDAQ:ACET) but has lowered the price target from $20 to $10.

August 10, 2023 | 7:44 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Adicet Bio's price target has been lowered from $20 to $10 by BTIG, though the Buy rating is maintained.
The lowering of the price target by BTIG indicates a potential decrease in the stock's value. However, the maintained Buy rating suggests that the stock is still expected to perform well in the long term. This could lead to short term negative impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100